|
Nuvelo Inc. was a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Corporate officers included Chairman Dr. George Rathmann (founder and CEO of Amgen), CEO Dr. Ted Love, and Executive Vice President Research & Development Dr. Michael Levy. On January 27, 2009, the company was acquired by ARCA Biopharma, Inc. in a reverse takeover transaction. ==The company== Nuvelo, Inc. was located at San Carlos, California and had approximately 250 employees. The Company’s development pipeline included: *Alfimeprase, a direct-acting fibrinolytic in Phase II development for the treatment of thrombotic-related disorders, including acute ischemic stroke and catheter occlusion.〔(Alfimeprase )〕 *NU172, a direct thrombin inhibitor in Phase I development for use as a short-acting anticoagulant during medical or surgical procedures.〔(NU172 )〕 *rNAPc2, an anti-thrombin anticoagulant being developed for the treatment of thrombosis in metastatic colorectal carcinoma. *NU206, a preclinical candidate for the treatment of chemotherapy and radiation therapy-induced mucositis and inflammatory bowel disease.〔(Medical News Today )〕 In addition, Nuvelo had research programs in leukemia therapeutic antibodies and Wnt signaling pathway therapeutics to expand its drug pipeline and create additional partnering and licensing opportunities.〔(Bloomberg Businessweek: Nuvelo Inc. )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Nuvelo」の詳細全文を読む スポンサード リンク
|